Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)

被引：0
|
作者：
Qiu, Haibo
Zhou, Zhi-Wei
Zhou, Ye
Wan, Xiangbin
Li, Ning
Tao, Kaixiong
Li, Yong
Wu, Xin
Chen, Zi
Liu, Lihui
Men, Lichuang
Wang, Hengbang
Liang, Eric
Wang, Cunlin
Jiang, Lixin
Yang, Dajun
Xu, Rui-Hua
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Med Coll, Wuhan, Peoples R China
[5] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[7] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[8] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11540
引用
收藏
页数：1
相关论文
共 33 条
  • [31] SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
    Demetri, GD
    Desai, J
    Fletcher, JA
    Morgan, JA
    Fletcher, CDM
    Kazanovicz, A
    Van den Abbeele, A
    Baum, C
    Maki, R
    Heinrich, MC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 195S - 195S
  • [32] Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
    Yoo, C.
    Ryu, M. -H.
    Na, Y. S.
    Ryoo, B. -Y.
    Park, S. R.
    Kang, Y. -K.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2272 - 2277
  • [33] In-vitro activity of the multi-targeted receptor tyrosine kinase inhibitor sunitinib malate (SU11248) against gastrointestinal stromal tumor (GIST) mutants refractory to imatinib mesylate.
    Prenen, H
    Cools, J
    Mentens, N
    Sciot, R
    Schöffski, P
    van Oosterom, AT
    Marynen, P
    Debiec-Rychter, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9024S - 9024S
1234